World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
58
Citations
9621
World Ranking
3562
National Ranking
1648

Michael C. Keefer publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Michael C. Keefer sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 147 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Michael C. Keefer D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Michael C. Keefer sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 58 D-Index — 30th percentile

30% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Michael C. Keefer is affiliated with the University of Rochester in the United States. Their research primarily focuses on immunology, microbiology, and medicine, with substantial contributions to the fields of virology, immunology, infectious diseases, molecular biology, and epidemiology.

The scientist's work covers multiple main topics, including:

  • HIV Research and Treatment
  • Immune Cell Function and Interaction
  • Vaccines and Immunoinformatics Approaches
  • T-cell and B-cell Immunology
  • HIV/AIDS Drug Development and Treatment
  • HIV/AIDS Research and Interventions
  • Hepatitis C Virus Research

Michael C. Keefer has published numerous papers in reputable venues. Frequent publication sources include:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • The Journal of Infectious Diseases
  • The Lancet HIV
  • JCI Insight
  • Cell Reports Medicine

Recent papers authored or co-authored by Keefer span important topics related to infectious diseases and vaccine development. Notable recent publications are:

  • Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study (2021) in The Lancet Infectious Diseases
  • Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study (2020) in The Lancet HIV
  • Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies (2021) in Clinical Infectious Diseases
  • Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention (2021) in JAMA Network Open
  • Robust antibody and cellular responses induced by DNA-only vaccination for HIV (2020) in JCI Insight

The scientist frequently collaborates with other researchers. Their most frequent co-authors include:

  • Georgia D. Tomaras
  • M. Juliana McElrath
  • Lawrence Corey
  • Paul Goepfert
  • Ian Frank

Best Publications

  • Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine

    Scott M. Hammer;Magdalena E. Sobieszczyk;Holly Janes;Shelly T. Karuna

  • Immunization with Envelope Subunit Vaccine Products Elicits Neutralizing Antibodies against Laboratory-Adapted but Not Primary Isolates of Human Immunodeficiency Virus Type 1

    J R Mascola;S W Snyder;O S Weislow;S M Belay

  • Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.

    Ann R Falsey;Magdalena E Sobieszczyk;Ian Hirsch;Stephanie Sproule

  • Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV-1MN gp120, HIV-1SF2 Recombinant gp120, or Both Vaccines in Seronegative Adults

    Mary Lou Clements-Mann;Kent Weinhold;Thomas J. Matthews;Barney S. Graham

  • A Canarypox Vaccine Expressing Multiple Human Immunodeficiency Virus Type 1 Genes Given Alone or with Rgp120 Elicits Broad and Durable CD8+ Cytotoxic T Lymphocyte Responses in Seronegative Volunteers

    Thomas G. Evans;Michael C. Keefer;Kent J. Weinhold;Mark Wolff

  • Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

    Spyros A. Kalams;Scott D. Parker;Marnie Elizaga;Barbara Metch

  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.

    Robert B. Belshe;Geoffrey J. Gorse;Mark J. Mulligan;Thomas G. Evans

  • Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

    Barney S. Graham;Thomas J. Matthews;Robert B. Belshe;Mary Lou Clements

  • Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

    Wilton B. Williams;Hua Xin Liao;M. Anthony Moody;Thomas B. Kepler

  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.

    Robert B. Belshe;Cladd Stevens;Geoffrey J. Gorse;Susan Buchbinder

  • Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

    Graham Bs;Belshe Rb;Clements Ml;Dolin R

  • A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

    Gavin J. Churchyard;Cecilia Morgan;Elizabeth Adams;John Hural

  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

    Thomas G. Evans;M.Juliana McElrath;Tom Matthews;David Montefiori

  • The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE).

    Thomas P Lodise;Susan L Rosenkranz;Matthew Finnemeyer;Scott Evans

  • Phase 2 Study of an HIV-1 Canarypox Vaccine (vCP1452) Alone and in Combination With rgp120: Negative Results Fail to Trigger a Phase 3 Correlates Trial

    Nina D. Russell;Nina D. Russell;Nina D. Russell;Barney S. Graham;Michael C. Keefer;M. Juliana McElrath;M. Juliana McElrath

  • Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

    Robert B. Belshe;Barney S. Graham;Michael C. Keefer;Geoffrey J. Gorse

  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A.

    Kalpana Gupta;Michael Hudgens;Lawrence Corey;M. Juliana McElrath

  • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

    Belshe Rb;Graham Bs;Keefer Mc;Gorse Gj

  • Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection

    Robert B. Belshe;Mary Lou Clements;Raphael Dolin;Barney S. Graham

  • High Titer HIV-1 V3-Specific Antibodies with Broad Reactivity but Low Neutralizing Potency in Acute Infection and Following Vaccination

    Katie L. Davis;Elin S. Gray;Penny L. Moore;Julie M. Decker

Frequent Co-Authors

Barney S. Graham
Barney S. Graham Morehouse School of Medicine
M. Juliana McElrath
M. Juliana McElrath University of Washington
David C. Montefiori
David C. Montefiori Duke University
Lawrence Corey
Lawrence Corey Fred Hutchinson Cancer Research Center
Georgia D. Tomaras
Georgia D. Tomaras Duke University
Kent J. Weinhold
Kent J. Weinhold Duke University
Raphael Dolin
Raphael Dolin Beth Israel Deaconess Medical Center
Robert B. Belshe
Robert B. Belshe Saint Louis University
Peter B. Gilbert
Peter B. Gilbert Fred Hutchinson Cancer Research Center
Lindsey R. Baden
Lindsey R. Baden Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various allied health careers, especially in nursing and healthcare fields. For those interested in expanding their clinical knowledge quickly, exploring an accelerated FNP program can be an excellent option to become a Family Nurse Practitioner faster while building on a strong foundation in immunology and patient care.

Additionally, individuals without a nursing background can transition smoothly into healthcare through programs like online RN programs for non nurses in Florida. These pathways provide accessible routes to becoming a registered nurse, often integrating immunology coursework essential for understanding disease processes and immune system functions.

For those seeking a quicker entry into nursing, options such as the easiest accelerated nursing programs offer streamlined curriculums designed to fast-track education without compromising quality. Likewise, LPN programs easy to get into provide foundational practical nursing education with manageable admission criteria, ideal for students interested in hands-on healthcare roles closely connected to immunology principles.

Choosing the right degree and career pathway not only complements your immunology studies but also positions you strongly for diverse healthcare roles focusing on disease prevention, immune health, and patient management.

Best Scientists Citing Michael C. Keefer

Trending Scientists